MedDRA preferred term

Uveitis: adverse event reports recording this term

13,320 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

13,320
reports recording the term: 0.1% of all reports; 1,059
reports, 12 months to June 2026: 1,074 in the 12 months before; 93.7%
marked serious by the reporter: 57.4% across all reports; 1%
record death among outcomes, as reported: 9.1% across all reports

"Uveitis" is a MedDRA preferred term recorded in 13,320 adverse event reports received by FDA, 0.1% of the database, from January 2004 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

1,059 reports recorded it in the 12 months to June 2026, close to the 1,074 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 93.7% are marked serious, 1% include death among the outcomes and 15.4% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Humira, Enbrel and Infliximab. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Humira	—	1,797	0.3%
Enbrel	Tumor necrosis factor blocker	930	0.2%
Infliximab	Tumor necrosis factor blocker	788	1.5%
Methotrexate	Folate analog metabolic inhibitor	752	0.4%
Inflectra	Tumor necrosis factor blocker	720	2.8%
Remicade	Tumor necrosis factor blocker	595	0.4%
Cosentyx	Interleukin-17A antagonist	556	0.4%
Adalimumab	Tumor necrosis factor blocker	539	1.4%
Prednisone	Corticosteroid	387	0.2%
Simponi	Tumor necrosis factor blocker	318	0.5%
Eylea	Vascular endothelial growth factor inhibitor	312	1.2%
Beovu	—	309	10.8%
Vabysmo	—	301	4.1%
Methotrexate sodium	Folate analog metabolic inhibitor	244	0.4%
Mycophenolate mofetil	Antimetabolite immunosuppressant	227	0.3%
Avastin	Vascular endothelial growth factor inhibitor	200	0.3%
Opdivo	Programmed death Receptor-1 blocking antibody	189	0.4%
Cimzia	Tumor necrosis factor blocker	187	0.2%
Etanercept	Tumor necrosis factor blocker	186	1%
Vedolizumab	Integrin receptor antagonist	184	0.3%
Sulfasalazine	Aminosalicylate	182	0.4%
Nivolumab	Programmed death Receptor-1 blocking antibody	181	0.4%
Rituximab	CD20-directed cytolytic antibody	172	0.1%
Prednisolone	Corticosteroid	157	0.2%
Tafinlar	Kinase inhibitor	146	1%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Tumor necrosis factor blocker	4,615	0.4%	0.5%
Folate analog metabolic inhibitor	1,004	0.3%	0%
Corticosteroid	929	0.1%	0%
Kinase inhibitor	880	0.1%	0%
Vascular endothelial growth factor inhibitor	839	0.5%	0.5%
Interleukin-17A antagonist	676	0.4%	0.9%
Programmed death Receptor-1 blocking antibody	556	0.2%	0.2%
Nonsteroidal anti-inflammatory drug	486	0.1%	0%
Interleukin-6 receptor antagonist	302	0.2%	0.2%
Integrin receptor antagonist	267	0.1%	0.1%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.1%13

2 to 112.4%324

12 to 172.4%319

18 to 4417.5%2,335

45 to 6422.4%2,978

65 to 749.5%1,261

75 and over6.7%897

Age not given39%5,193

Patient sex

Female50.3%6,695

Male30.1%4,015

Not given19.6%2,610

Grey bar: all 20,646,523 reports in the database. 28.8% of these reports give the United States as the country.

Questions about "Uveitis"

What does "Uveitis" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record uveitis?

13,320 reports through June 2026 (0.1% of all reports), 1,059 of them in the latest 12 months.

Which drugs appear most often in these reports?

Humira (1,797), Enbrel (930), Infliximab (788), Methotrexate (752) and Inflectra (720). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.